These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23039281)

  • 1. Pharmacy compounding primer for physicians: prescriber beware.
    Sellers S; Utian WH
    Drugs; 2012 Nov; 72(16):2043-50. PubMed ID: 23039281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk and liabilities of prescribing compounded medications.
    Randell MD; Duffy PJ
    Postgrad Med; 2014 Jul; 126(4):178-80. PubMed ID: 25276868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Extemporaneous Prescriptions Prescribed by Dermatovenerologists in Latvia and Comparison with Standardized Compounded Preparation Monographs of Germany and USA.
    Kiseļova O; Mauriņa B; Šidlovska V
    Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31936697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States.
    Song YK; Han N; Burckart GJ; Oh JM
    Clin Pharmacol Ther; 2020 Mar; 107(3):530-540. PubMed ID: 31544241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing of FDA-approved and compounded hormone therapy differs by specialty.
    Constantine GD; Archer DF; Graham S; Bernick BA; Mirkin S
    Menopause; 2016 Oct; 23(10):1075-82. PubMed ID: 27648594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey.
    Pinkerton JV; Constantine GD
    Menopause; 2016 Apr; 23(4):359-67. PubMed ID: 26645819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of FDA drug recalls: A 30-month analysis.
    Hall K; Stewart T; Chang J; Freeman MK
    Am J Health Syst Pharm; 2016 Feb; 73(4):235-40. PubMed ID: 26843501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.
    AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S
    BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compounding botanicals: a legal perspective.
    Valentino JG; Bormel FG
    J Am Pharm Assoc (Wash); 1999; 39(4):537-44. PubMed ID: 10467820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary care physicians' use of FDA-approved prescription drug labels.
    Sullivan HW; O'Donoghue AC; Aikin KJ
    J Am Board Fam Med; 2014; 27(5):694-8. PubMed ID: 25201939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
    Pinkerton JV; Pickar JH
    Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Warns of Hidden Prescription Drugs in Dietary Supplements.
    Aschenbrenner DS
    Am J Nurs; 2019 May; 119(5):22-23. PubMed ID: 31033549
    [No Abstract]   [Full Text] [Related]  

  • 17. Determinants and frequency of pharmaceutical compounding in pharmacy practice in Palestine.
    Zaid AN; Al-Ramahi R; Shahed Q; Saleh B; Elaraj J
    Int J Pharm Pract; 2012 Feb; 20(1):9-14. PubMed ID: 22236175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geographic variation in drug safety: potentially unsafe prescribing of medications and prescriber responsiveness to safety alerts.
    Feifer RA; James JM
    J Manag Care Pharm; 2010 Apr; 16(3):196-205. PubMed ID: 20331324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Expands List of "Do Not Compound" Drug Products.
    Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services
    J Pain Palliat Care Pharmacother; 2017 Mar; 31(1):76-78. PubMed ID: 28287350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.